Affects of Apatinib in the Invasion Ability of Non-small Cell Lung Cancer Cells / 医药导报

Objective To observe the effect of apatinib on the invasion ability and epithelial-mesenchymal transition (EMT) of non-small cell lung cancer (NSCLC) cell line A549 and H460.Methods Different doses of apatinib were incubated with the A549 and H460 cells,then the effect of apatinib on the invasion of A549 cells was detected by Transwell assay,and the change of cell morphology was observed by optical microscope,and the expression of EMT related proteins were detected by Western blotting.Results The cell viability of A549 and H460 have no change when the concentration of apatinib was under 120 nmol·L-1.Therefore,60 nmol·L-1 and 120 nmol·L-1 apatinib were used in the further experiments.The invasion of A549 cells was reduced after apatinib incubation for 48 h,with cell morphology changes,and the expression of E-cadherin was enhanced,with the depresion of N-cadherin,Vimentin and Snail,which were related to the progress of EMT.Conclusion Apatinib could induce the MET,and reduce the invasion ability of A549 and H460 cells.

Advanced Progress of Targeted Therapeutic Drugs in Treating Non-Small Cell Lung Cancer / 医药导报

Targeted therapeutic drug,having such advantages as targeting,safety,convenience,etc,is increasingly favored by non-small cell lung cancer (NSCLC) patients.At present,there are many kinds of molecular targeted drugs used in clinic,and remarkable efficacy was achieved,and the pain caused by conventional chemotherapy was avoided.At the same time,with the deepening of the understanding of the mechanism of tumor immune,new targeted drugs will also continue to be developed.The emergence of the third generation EGFR-TKI brings new hope for first generation EGFR-TKI resistant patients.Combined use of different immune therapeutic agents,combined application of immunotherapy drugs and cytotoxic chemotherapy drugs and radiotherapy,and the exploration of its predictive biomarkers will become a hot spot in the research of lung cancer.This will undoubtedly bring a new dawn for the treatment of NSCLC.Based on the domestic and foreign research literatures and related materials,this article reviews the latest research progress of various molecular targeted drugs for treatment of NSCLC.

Effect of Curcumin on Non-Small Cell Lung Cancer A549 Cells / 医药导报

Objective To study the inhibitory effect of curcumin on the proliferation,migration and invasion of non-small cell lung cancer cell A549,and to discuss further if it is closely related to the expression of c-Jun N-terminal kinase (JNK) and relative protein p38.Methods A549 cells were cultured by conventional method,and then treated with different concentration of curcumin (10,20,40,80 μmol · L-1).The proliferation,migration and invasion of A549 cells were measured by real-time cellular analysis (RTCA).The expression levels of JNK,p-JNK,p38 and P-p38 were detected by real-time PCR and Western blotting.Results Curcumin showed an antiproliferation effect against A549 cells with IC50 =40 μmol · L-1,and curcumin exhibited obviously inhibitory effect on the migration and invasion of A549 cells.Additionally,compared with control group,curcumin suppressed the expression of JNK and p38 at the gene level,and significantly inhibited the expression of JNK,P-JNK,p38 and p38 (P＜0.05) at the protein level.Conclusion These results demonstrated that curcumin can inhibit the proliferation,migration and invasion of A549 cells via reducing the level of JNK,p38 phosphorylation,and blocking JNK signal transduction pathway.